Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group
Authors
Keywords
-
Journal
PROSTATE
Volume 78, Issue 11, Pages 775-789
Publisher
Wiley
Online
2018-05-02
DOI
10.1002/pros.23642
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA–targeted PET Imaging Studies
- (2018) Steven P. Rowe et al. EUROPEAN UROLOGY
- Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control
- (2018) Clemens Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- Prostate Specific Membrane Antigen Targeted 18 F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study
- (2018) Michael A. Gorin et al. JOURNAL OF UROLOGY
- Positron Emission Tomography/Computed Tomography–Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker for Metastatic Castration-Resistant Prostate Cancer
- (2018) Josef J. Fox et al. JAMA Oncology
- 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
- (2017) Mike Sathekge et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- 68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning
- (2017) Jeremie Calais et al. JOURNAL OF NUCLEAR MEDICINE
- Impact of68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence
- (2017) Jeremie Calais et al. JOURNAL OF NUCLEAR MEDICINE
- Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT
- (2017) Matthias Eiber et al. JOURNAL OF NUCLEAR MEDICINE
- Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen–Targeted PET Imaging: PSMA-RADS Version 1.0
- (2017) Steven P. Rowe et al. JOURNAL OF NUCLEAR MEDICINE
- Phase 2 Study of 99m Tc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection
- (2017) Karolien E. Goffin et al. JOURNAL OF NUCLEAR MEDICINE
- The Impact of68Ga-PSMA PET/CT on Management Intent in Prostate Cancer: Results of an Australian Prospective Multicenter Study
- (2017) Paul J. Roach et al. JOURNAL OF NUCLEAR MEDICINE
- Potential of asphericity as a novel diagnostic parameter in the evaluation of patients with 68Ga-PSMA-HBED-CC PET-positive prostate cancer lesions
- (2017) Sebastian Meißner et al. EJNMMI Research
- A dextran-based probe for the targeted magnetic resonance imaging of tumours expressing prostate-specific membrane antigen
- (2017) Guanshu Liu et al. Nature Biomedical Engineering
- Phase I trial of fractionated-dose 177lutetium radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) in patients (pts) with metastatic castration-resistant prostate cancer (metCRPC).
- (2017) S. T. Tagawa et al. JOURNAL OF CLINICAL ONCOLOGY
- 68Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment
- (2016) Pim J. van Leeuwen et al. BJU INTERNATIONAL
- Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer
- (2016) Kambiz Rahbar et al. CLINICAL NUCLEAR MEDICINE
- 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment
- (2016) Madhav Prasad Yadav et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Response and Tolerability of a Single Dose of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Analysis
- (2016) K. Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- (2S)-2-(3-(1-Carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic Acid for PSMA-Targeted -Particle Radiopharmaceutical Therapy
- (2016) A. P. Kiess et al. JOURNAL OF NUCLEAR MEDICINE
- German Multicenter Study Investigating 177 Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
- (2016) Kambiz Rahbar et al. JOURNAL OF NUCLEAR MEDICINE
- Semiquantitative Parameters in PSMA-Targeted PET Imaging with 18 F-DCFPyL: Variability in Normal-Organ Uptake
- (2016) Xin Li et al. JOURNAL OF NUCLEAR MEDICINE
- PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy
- (2016) R. P. Baum et al. JOURNAL OF NUCLEAR MEDICINE
- 225Ac-PSMA-617 for PSMA-Targeted -Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer
- (2016) C. Kratochwil et al. JOURNAL OF NUCLEAR MEDICINE
- PSMA-Based Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer: The Bad Berka Experience Since 2013
- (2016) H. R. Kulkarni et al. JOURNAL OF NUCLEAR MEDICINE
- Systemic Radioligand Therapy with 177Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer
- (2016) Matthias M. Heck et al. JOURNAL OF UROLOGY
- PSMA-Based [18F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer
- (2016) Steven P. Rowe et al. MOLECULAR IMAGING AND BIOLOGY
- Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [177Lu]DKFZ-PSMA-617
- (2016) Melanie Hohberg et al. MOLECULAR IMAGING AND BIOLOGY
- Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer
- (2016) Wolfgang P. Fendler et al. Oncotarget
- Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent
- (2016) Kristell L.S. Chatalic et al. Theranostics
- Synthesis and Evaluation of GdIII-Based Magnetic Resonance Contrast Agents for Molecular Imaging of Prostate-Specific Membrane Antigen
- (2015) Sangeeta Ray Banerjee et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer
- (2015) N. Pandit-Taskar et al. CLINICAL CANCER RESEARCH
- Pre-therapeutic dosimetry of normal organs and tissues of 177Lu-PSMA-617 prostate-specific membrane antigen (PSMA) inhibitor in patients with castration-resistant prostate cancer
- (2015) Levent Kabasakal et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Dosimetry for 177Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer
- (2015) Andreas Delker et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Prostate-specific Membrane Antigen–radioguided Surgery for Metastatic Lymph Nodes in Prostate Cancer
- (2015) Tobias Maurer et al. EUROPEAN UROLOGY
- Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
- (2015) M. Bene ova et al. JOURNAL OF NUCLEAR MEDICINE
- Comparison of [18F]DCFPyL and [68Ga]Ga-PSMA-HBED-CC for PSMA-PET Imaging in Patients with Relapsed Prostate Cancer
- (2015) Markus Dietlein et al. MOLECULAR IMAGING AND BIOLOGY
- Initial Evaluation of [18F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer
- (2015) Zsolt Szabo et al. MOLECULAR IMAGING AND BIOLOGY
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Addition of PSMA ADC to enzalutamide therapy significantly improves survival in in vivo model of castration resistant prostate cancer
- (2015) Vincent A. DiPippo et al. PROSTATE
- Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors
- (2015) Neeta Pandit-Taskar et al. EJNMMI Research
- A Modular Strategy to Prepare Multivalent Inhibitors of Prostate-Specific Membrane Antigen (PSMA)
- (2015) Sangeeta Ray Banerjee et al. Oncotarget
- Real-time, Near-Infrared Fluorescence Imaging with an Optimized Dye/Light Source/Camera Combination for Surgical Guidance of Prostate Cancer
- (2014) B. P. Neuman et al. CLINICAL CANCER RESEARCH
- Prostate-Specific Membrane Antigen Protein Expression in Tumor Tissue and Risk of Lethal Prostate Cancer
- (2013) J. L. Kasperzyk et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer
- (2013) S. T. Tagawa et al. CLINICAL CANCER RESEARCH
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- 68Ga-Complex Lipophilicity and the Targeting Property of a Urea-Based PSMA Inhibitor for PET Imaging
- (2012) Matthias Eder et al. BIOCONJUGATE CHEMISTRY
- Targeted, Activatable, In Vivo Fluorescence Imaging of Prostate-Specific Membrane Antigen (PSMA) Positive Tumors Using the Quenched Humanized J591 Antibody–Indocyanine Green (ICG) Conjugate
- (2011) Takahito Nakajima et al. BIOCONJUGATE CHEMISTRY
- 2-(3- -Ureido)-Pentanedioic Acid, [18F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer
- (2011) Y. Chen et al. CLINICAL CANCER RESEARCH
- Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen
- (2011) M. J. Evans et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The distribution of the therapeutic monoclonal antibodies cetuximab and trastuzumab within solid tumors
- (2010) Carol M Lee et al. BMC CANCER
- High level PSMA expression is associated with early psa recurrence in surgically treated prostate cancer
- (2010) Sarah Minner et al. PROSTATE
- N-[N-[(S)-1,3-Dicarboxypropyl]Carbamoyl]-4-[18F]Fluorobenzyl-L-Cysteine, [18F]DCFBC: A New Imaging Probe for Prostate Cancer
- (2008) R. C. Mease et al. CLINICAL CANCER RESEARCH
- Phase I Trial of the Prostate-Specific Membrane Antigen–Directed Immunoconjugate MLN2704 in Patients With Progressive Metastatic Castration-Resistant Prostate Cancer
- (2008) Matthew D. Galsky et al. JOURNAL OF CLINICAL ONCOLOGY
- Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA)
- (2008) Sangeeta R. Banerjee et al. JOURNAL OF MEDICINAL CHEMISTRY
- Cell-Surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen
- (2008) Tiancheng Liu et al. PROSTATE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started